Biotechnology

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif.  , July 25, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces thatthe investigation...

2024-07-25 17:46 2064

AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event

Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently hosts Insilico Medicine...

2024-07-24 21:00 1454

IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Multiple Sclerosis

SHANGHAI, NANJING, China and SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, announced that the investigational new d...

2024-07-24 09:52 1731

FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, July 24, 2024  /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...

2024-07-24 08:10 1845

Telix Successfully Prices A$650 Million Convertible Bonds

MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...

2024-07-24 07:51 1840

Origin Agritech Announces Long-Term Revenue Projections Across Key Product Lines Through 2029

BEIJING, July 23, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, is pleased to announce its revenue projections for key product lines through the year 2029. Revenue Projections Revenue from hybrid seeds a...

2024-07-23 20:00 4096

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...

2024-07-23 16:35 1752

SND Introduces Revolutionary Moderated Drinking Treatment Program

TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...

2024-07-23 16:29 1812

QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs

SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX , a computational drug discovery company, today announced a collaboration with Prelude Therapeutics , a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets....

2024-07-23 08:00 1985

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease

* Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials * Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ --  DiscGenics, Inc., a privately held, l...

2024-07-23 08:00 1646

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...

2024-07-22 19:48 2517

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...

2024-07-22 19:00 2394

Join Hands for a Brighter Future!2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition Overseas Event (Hong Kong SAR Division) Concluded Successfully

HONG KONG, July 22, 2024 /PRNewswire/ -- On July 17, 2024, the Hong Kong SAR division of the 2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition concluded successfully. Top scientists, business leaders, government officials, and elite entrepreneurs from around the world gathe...

2024-07-22 16:41 2052

Duke-NUS launches LIVE Ventures, a S$20 million incubator to accelerate research commercialisation

* New incubator aims to tap industry experts to bridge the knowledge and funding gap to enhance bench-to-bedside success * LIVE Ventures provides up to $500,000 for high-potential academic research projects SINGAPORE, July 22, 2024 /PRNewswire/ -- Duke-NUS Medical School today launched LIVE V...

2024-07-22 10:00 2034

Agilent Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit

SINGAPORE, July 22, 2024 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) today an...

2024-07-22 09:12 2396

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...

2024-07-22 09:00 1936

Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors

HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 21, 2024 /PRNewswire/ -- Full-Life Technologies, a fully integrated global radiotherapeutics company, today announcedthe appointment of Ted Myles to Full-Life's Board of Directors. Mr. Myles will serve as chairman of the audit c...

2024-07-22 08:00 1277

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-07-22 08:00 3032

111 Announces Appointment of New Auditor

SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced  the appointment o...

2024-07-19 20:45 3051

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-07-19 07:15 2843
1 ... 20212223242526 ... 306